Skip to main content
SpringerLink
Log in

Inpatient Management of Patients with Diabetes and Kidney Disease

  • Chapter
  • First Online:
Diabetes Management in Hospitalized Patients

Part of the book series: Contemporary Endocrinology ((COE))

  • 299 Accesses

Abstract

Patients with diabetes mellitus (DM) and chronic kidney disease (CKD) are a vulnerable population in the hospital with high rates of multifactorial hypo- and hyperglycemia. Diabetes treatment is complicated by decreased drug excretion, accumulation of metabolites, side effects, and the presence of other comorbidities. Patients experience large glucose fluctuations especially in advanced renal disease which makes blood glucose (BG) management challenging. This chapter outlines the pathophysiology, BG targets, and medication adjustments for different stages of CKD and outlines the role of emerging technology to improve care of this high-risk group.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Aldukhayel A. Prevalence of diabetic nephropathy among type 2 diabetic patients in some of the Arab countries. Int J Health Sci. 2017;11:1–4.

    Google Scholar 

  2. Afkarian M, Zelnick LR, Hall YN, Heagerty PJ, Tuttle K, Weiss NS, de Boer IH. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA. 2016;316:602–10.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Thakar CV, Christianson A, Himmelfarb J, Leonard AC. Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus. Clin J Am Soc Nephrol CJASN. 2011;6:2567–72.

    Article  CAS  PubMed  Google Scholar 

  4. Hung AM, Siew ED, Wilson OD, et al. Risk of hypoglycemia following hospital discharge in patients with diabetes and acute kidney injury. Diabetes Care. 2018;41:503–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Salah HM, Al’Aref SJ, Khan MS, et al. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis. Cardiovasc Diabetol. 2022;21:20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Baldwin D, Zander J, Munoz C, Raghu P, DeLange-Hudec S, Lee H, Emanuele MA, Glossop V, Smallwood K, Molitch M. A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency. Diabetes Care. 2012;35:1970–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Galindo RJ, Pasquel FJ, Fayfman M, Tsegka K, Dhruv N, Cardona S, Wang H, Vellanki P, Umpierrez GE. Clinical characteristics and outcomes of patients with end-stage renal disease hospitalized with diabetes ketoacidosis. BMJ Open Diabetes Res Care. 2020;8:e000763.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Charpentier G, Riveline J, Varroud-Vial M. Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab. 2000;26:73–85.

    CAS  PubMed  Google Scholar 

  9. Abe M, Kalantar-Zadeh K. Haemodialysis-induced hypoglycaemia and glycaemic disarrays. Nat Rev Nephrol. 2015;11:302–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Shurraw S, Hemmelgarn B, Lin M, et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med. 2011;171:1920–7.

    Article  PubMed  Google Scholar 

  11. de Boer IH, Caramori ML, Chan JCN, et al. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;98:S1–S115.

    Article  Google Scholar 

  12. Ansari A, Thomas S, Goldsmith D. Assessing glycemic control in patients with diabetes and end-stage renal failure. Am J Kidney Dis. 2003;41:523–31.

    Article  PubMed  Google Scholar 

  13. Inaba M, Okuno S, Kumeda Y, et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol JASN. 2007;18:896–903.

    Article  CAS  PubMed  Google Scholar 

  14. Joubert M, Fourmy C, Henri P, Ficheux M, Lobbedez T, Reznik Y. Effectiveness of continuous glucose monitoring in dialysis patients with diabetes: the DIALYDIAB pilot study. Diabetes Res Clin Pract. 2015;107:348–54.

    Article  CAS  PubMed  Google Scholar 

  15. Hissa MRN, Hissa PNG, Guimarães SB, Hissa MN. Use of continuous glucose monitoring system in patients with type 2 mellitus diabetic during hemodialysis treatment. Diabetol Metab Syndr. 2021;13:104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Weber MR, Diebold M, Wiesli P, Kistler AD. Accuracy of flash glucose monitoring in hemodialysis patients with and without diabetes mellitus. Exp Clin Endocrinol Diabetes. 2023;131:132–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Bally L, Gubler P, Thabit H, et al. Fully closed-loop insulin delivery improves glucose control of inpatients with type 2 diabetes receiving hemodialysis. Kidney Int. 2019;96:593–6.

    Article  CAS  PubMed  Google Scholar 

  18. Rossing P, Caramori ML, Chan JCN, et al. KDIGO 2022 clinical practice guideline for diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102:S1–S127.

    Article  Google Scholar 

  19. Biesenbach G, Raml A, Schmekal B, Eichbauer-Sturm G. Decreased insulin requirement in relation to GFR in nephropathic type 1 and insulin-treated type 2 diabetic patients. Diabet Med J Br Diabet Assoc. 2003;20:642–5.

    Article  CAS  Google Scholar 

  20. Dobri GA, Lansang MC. How should we manage insulin therapy before surgery? Cleve Clin J Med. 2013;80:702–4.

    Article  PubMed  Google Scholar 

  21. Umpierrez GE, Hellman R, Korytkowski MT, Kosiborod M, Maynard GA, Montori VM, Seley JJ, Van den Berghe G. Management of Hyperglycemia in hospitalized patients in non-critical care setting: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:16–38.

    Article  CAS  PubMed  Google Scholar 

  22. Broberg B, Madsen JL, Fuglsang S, Holst JJ, Christensen KB, Rydahl C, Idorn T, Feldt-Rasmussen B, Hornum M. Gastrointestinal motility in patients with end-stage renal disease on chronic hemodialysis. Neurogastroenterol Motil. 2019;31:e13554.

    Article  PubMed  Google Scholar 

  23. Toyoda M, Kimura M, Yamamoto N, Miyauchi M, Umezono T, Suzuki D. Insulin glargine improves glycemic control and quality of life in type 2 diabetic patients on hemodialysis. J Nephrol. 2012;25:989–95.

    Article  CAS  PubMed  Google Scholar 

  24. Marchant K. The renal diabetic nurse specialist...A luxury or an essential player? EDTNAERCA J Engl Ed. 2002;28:67–9.

    CAS  Google Scholar 

  25. Bouchi R, Babazono T, Onuki T, Mitamura K, Ishikawa Y, Uchigata Y, Iwamoto Y. Administration of insulin glargine thrice weekly by medical staff at a dialysis unit: a new insulin regimen for diabetic management in physically impaired patients undergoing hemodialysis. Diabetol Int. 2011;2:197–201.

    Article  Google Scholar 

  26. Sobngwi E, Enoru S, Ashuntantang G, Azabji-Kenfack M, Dehayem M, Onana A, Biwole D, Kaze F, Gautier J-F, Mbanya J-C. Day-to-day variation of insulin requirements of patients with type 2 diabetes and end-stage renal disease undergoing maintenance hemodialysis. Diabetes Care. 2010;33:1409–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Kiss I, Arold G, Roepstorff C, Bøttcher SG, Klim S, Haahr H. Insulin degludec: pharmacokinetics in patients with renal impairment. Clin Pharmacokinet. 2014;53:175–83.

    Article  CAS  PubMed  Google Scholar 

  28. Jacobsen L, Popescu G, Plum A. Pharmacokinetics of insulin detemir in subjects with renal or hepatic impairment. Diabetologia. 2002;45:A259–60.

    Google Scholar 

  29. Aisenpreis U, Pfützner A, Giehl M, Keller F, Jehle PM. Pharmacokinetics and pharmacodynamics of insulin Lispro compared with regular insulin in haemodialysis patients with diabetes mellitus. Nephrol Dial Transplant. 1999;14(Suppl 4):5–6.

    Article  PubMed  Google Scholar 

  30. Kulozik F, Hasslacher C. Insulin requirements in patients with diabetes and declining kidney function: differences between insulin analogues and human insulin? Ther Adv Endocrinol Metab. 2013;4:113–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Raimann JG, Kruse A, Thijssen S, Kuntsevich V, Dabel P, Bachar M, Diaz-Buxo JA, Levin NW, Kotanko P. Metabolic effects of dialyzate glucose in chronic hemodialysis: results from a prospective, randomized crossover trial. Nephrol Dial Transplant. 2012;27:1559–68.

    Article  CAS  PubMed  Google Scholar 

  32. Gianchandani RY, Neupane S, Heung M. Hypoglycemia in hospitalized hemodialysis patients with diabetes: an observational study. J Diabetes Sci Technol. 2018;12:33–8.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Apel J, Reutrakul S, Baldwin D. Hypoglycemia in the treatment of hyperkalemia with insulin in patients with end-stage renal disease. Clin Kidney J. 2014;7:248–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Schafers S, Naunheim R, Vijayan A, Tobin G. Incidence of hypoglycemia following insulin-based acute stabilization of hyperkalemia treatment. J Hosp Med. 2012;7:239–42.

    Article  PubMed  Google Scholar 

  35. Coca A, Valencia AL, Bustamante J, Mendiluce A, Floege J. Hypoglycemia following intravenous insulin plus glucose for hyperkalemia in patients with impaired renal function. PLoS One. 2017;12:e0172961.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Moussavi K, Garcia J, Tellez-Corrales E, Fitter S. Reduced alternative insulin dosing in hyperkalemia: a meta-analysis of effects on hypoglycemia and potassium reduction. Pharmacother J Hum Pharmacol Drug Ther. 2021;41:598–607.

    Article  CAS  Google Scholar 

  37. Farina N, Anderson C. Impact of dextrose dose on hypoglycemia development following treatment of hyperkalemia. Ther Adv Drug Saf. 2018;9:323–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Iyengar R, Franzese J, Gianchandani R. Inpatient glycemic Management in the Setting of renal insufficiency/failure/dialysis. Curr Diab Rep. 2018;18:75.

    Article  PubMed  Google Scholar 

  39. Quellhorst E. Insulin therapy during peritoneal dialysis: pros and cons of various forms of administration. J Am Soc Nephrol. 2002;13:S92–6.

    Article  CAS  PubMed  Google Scholar 

  40. Almalki MH, Altuwaijri MA, Almehthel MS, Sirrs SM, Singh RS. Subcutaneous versus intraperitoneal insulin for patients with diabetes mellitus on continuous ambulatory peritoneal dialysis: meta-analysis of non-randomized clinical trials. Clin Investig Med Med Clin Exp. 2012;35:E132–43.

    Article  Google Scholar 

  41. American Diabetes Association Professional Practice Committee. 16. Diabetes Care in the Hospital: standards of medical care in diabetes—2022. Diabetes Care. 2021;45:S244–53.

    Article  Google Scholar 

  42. Korytkowski MT, Muniyappa R, Antinori-Lent K, et al. Management of hyperglycemia in hospitalized adult patients in non-critical care settings: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2022;dgac278:2101.

    Article  Google Scholar 

  43. Pasquel FJ, Gianchandani R, Rubin DJ, et al. Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol. 2017;5:125–33.

    Article  CAS  PubMed  Google Scholar 

  44. Garg R, Schuman B, Hurwitz S, Metzger C, Bhandari S. Safety and efficacy of saxagliptin for glycemic control in non-critically ill hospitalized patients. BMJ Open Diabetes Res Care. 2017;5:e000394.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Vellanki P, Rasouli N, Baldwin D, et al. Glycaemic efficacy and safety of linagliptin compared to a basal-bolus insulin regimen in patients with type 2 diabetes undergoing non-cardiac surgery: a multicentre randomized clinical trial. Diabetes Obes Metab. 2019;21:837–43.

    Article  CAS  PubMed  Google Scholar 

  46. Umpierrez GE, Gianchandani R, Smiley D, et al. Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study. Diabetes Care. 2013;36:3430–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130:1579–88.

    Article  CAS  PubMed  Google Scholar 

  48. Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, Botros FT. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018;6:605–17.

    Article  CAS  PubMed  Google Scholar 

  49. Mann JFE, Fonseca VA, Poulter NR, Raz I, Idorn T, Rasmussen S, von Scholten BJ, Mosenzon O, Investigators on behalf of the LT. Safety of liraglutide in type 2 diabetes and chronic kidney disease. Clin J Am Soc Nephrol. 2020;15:465–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Fayfman M, Galindo RJ, Rubin DJ, et al. A randomized controlled trial on the safety and efficacy of exenatide therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes. Diabetes Care. 2019;42:450–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Kaneko S, Ueda Y, Tahara Y. GLP1 receptor agonist liraglutide is an effective therapeutic option for perioperative glycemic control in type 2 diabetes within enhanced recovery after surgery (ERAS) protocols. Eur Surg Res Eur Chir Forsch Rech Chir Eur. 2018;59:349–60.

    CAS  Google Scholar 

  52. Verma V, Kotwal N, Upreti V, Nakra M, Singh Y, Shankar KA, Nachankar A, Kumar KVSH. Liraglutide as an alternative to insulin for glycemic control in intensive care unit: a randomized, open-label, clinical study. Indian J Crit Care Med Peer-Rev. 2017;21:568–72.

    Article  CAS  Google Scholar 

  53. American Diabetes Association Professional Practice Committee. 11. Chronic kidney disease and risk management: standards of medical care in diabetes—2022. Diabetes Care. 2021;45:S175–84.

    Article  Google Scholar 

  54. Bakris GL, Molitch M. Are all patients with type 1 diabetes destined for dialysis if they live long enough? Probably not. Diabetes Care. 2018;41(3):389–90.

    Article  PubMed  Google Scholar 

  55. Schwartz AV, Chen H, Ambrosius WT, et al. Effects of TZD Use and Discontinuation on Fracture Rates in ACCORD Bone Study. J Clin Endocrinol Metab. 2015;100:4059–66.

    Google Scholar 

  56. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373:2117–28.

    Google Scholar 

  57. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85:962–71.

    Google Scholar 

  58. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016;375:323–34.

    Google Scholar 

  59. Perkovic V, de Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6:691–704.

    Google Scholar 

  60. Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7:606–17.

    Google Scholar 

  61. Rossing P, Caramori ML, Chan JCN, et al. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International. 2022;102(5):S1−127.

    Google Scholar 

  62. Research C for DE and (2022) FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. FDA.

    Google Scholar 

  63. Lin C, Zhu X, Cai X, Yang W, Lv F, Nie L, Ji L. SGLT2 inhibitors and lower limb complications: an updated meta‐analysis. Cardiovasc Diabetol. 2021;20:91.

    Google Scholar 

  64. Tzamaloukas AH, Ing TS, Siamopoulos KC, Rohrscheib M, Elisaf MS, Raj DSC, Murata GH. Body fluid abnormalities in severe hyperglycemia in patients on chronic dialysis: theoretical analysis. J Diabetes Complications. 2007;21:374–80.

    Google Scholar 

  65. Kazempour-Ardebili S, Lecamwasam VL, Dassanyake T, Frankel AH, Tam FWK, Dornhorst A, Frost G, Turner JJO. Assessing glycemic control in maintenance hemodialysis patients with type 2 diabetes. Diabetes Care. 2009;32:1137–42.

    Google Scholar 

  66. Umpierrez GE, Cuervo R, Karabell A, Latif K, Freire AX, Kitabchi AE. Treatment of diabetic ketoacidosis with subcutaneous insulin aspart. Diabetes Care. 2004;27:1873–78.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cedars-Sinai Medical Center, Los Angeles, CA, USA

    Erica Patel, Steve Kim & Roma Gianchandani

Authors
  1. Erica Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steve Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roma Gianchandani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roma Gianchandani .

Editor information

Editors and Affiliations

  1. Division of Endocrinology, Long Island Jewish Medical Center, Northwell Health, New Hyde Park, NY, USA

    Rifka C. Schulman-Rosenbaum

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Patel, E., Kim, S., Gianchandani, R. (2023). Inpatient Management of Patients with Diabetes and Kidney Disease. In: Schulman-Rosenbaum, R.C. (eds) Diabetes Management in Hospitalized Patients. Contemporary Endocrinology. Springer, Cham. https://doi.org/10.1007/978-3-031-44648-1_23

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-44648-1_23

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-44647-4

  • Online ISBN: 978-3-031-44648-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation